CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 679,000 shares, a growth of 86.2% from the September 15th total of 364,600 shares. Based on an average trading volume of 4,670,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of CNS Pharmaceuticals

A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC grew its position in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 94,246 shares of the company’s stock after purchasing an additional 81,094 shares during the quarter. Virtu Financial LLC owned approximately 0.80% of CNS Pharmaceuticals worth $34,000 as of its most recent filing with the SEC. 14.02% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Maxim Group raised CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research report on Tuesday, September 10th.

CNS Pharmaceuticals Price Performance

CNS Pharmaceuticals stock opened at $0.12 on Monday. CNS Pharmaceuticals has a 1-year low of $0.10 and a 1-year high of $137.50. The stock has a market cap of $170,706.90, a PE ratio of 0.00 and a beta of 2.57. The stock’s fifty day moving average is $0.15 and its two-hundred day moving average is $4.63.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share for the quarter.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.